Pluri Inc (PLUR)

May 27, 2025, 7:00 AM EDT - 11 days ago

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

BCLI

Apr 28, 2025, 8:00 AM EDT - 5 weeks ago

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

Mar 5, 2025, 7:00 AM EST - 3 months ago

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

Feb 19, 2025, 9:01 AM EST - 3 months ago

Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

Jan 23, 2025, 7:15 AM EST - 4 months ago

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

Dec 19, 2024, 8:00 AM EST - 6 months ago

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

Nov 12, 2024, 1:00 PM EST - 7 months ago

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

Nov 11, 2024, 6:00 AM EST - 7 months ago

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

BCLI

Jul 18, 2024, 2:30 AM EDT - 11 months ago

Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates

Jun 18, 2024, 12:45 PM EDT - 1 year ago

Pluri: Biotech Play With Several Opportunities Across Different Sectors

Jun 18, 2024, 6:30 AM EDT - 1 year ago

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

Jun 6, 2024, 6:45 AM EDT - 1 year ago

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract

May 20, 2024, 7:00 AM EDT - 1 year ago

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

May 2, 2024, 7:00 AM EDT - 1 year ago

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Mar 28, 2024, 7:15 AM EDT - 1 year ago

Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Mar 27, 2024, 7:00 AM EDT - 1 year ago

Pluri Inc. Announces 1-for-8 Reverse Share Split

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Mar 19, 2024, 4:00 AM EDT - 1 year ago

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Mar 6, 2024, 7:00 AM EST - 1 year ago

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Feb 28, 2024, 7:00 AM EST - 1 year ago

Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Jan 23, 2024, 2:00 AM EST - 1 year ago

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Jan 8, 2024, 7:00 AM EST - 1 year ago

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Aug 16, 2023, 7:00 AM EDT - 1 year ago

Pluri's PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

Jul 13, 2023, 2:00 AM EDT - 2 years ago

Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

Jul 11, 2023, 2:00 AM EDT - 2 years ago

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri's PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Apr 27, 2023, 7:00 AM EDT - 2 years ago

Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products

Mar 13, 2023, 8:00 AM EDT - 2 years ago

Israel's Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity

Dec 22, 2022, 7:00 AM EST - 2 years ago

Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept

Dec 15, 2022, 4:05 PM EST - 2 years ago

Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

Nov 10, 2022, 7:00 AM EST - 2 years ago

Pluri wins BioTech Breakthrough Cell Innovation of the Year Award

Oct 31, 2022, 8:00 AM EDT - 2 years ago

Pluri to Present and Participate in Upcoming Conferences

Sep 29, 2022, 7:00 AM EDT - 2 years ago

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

Sep 6, 2022, 7:00 AM EDT - 2 years ago

€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment

Jul 25, 2022, 7:00 AM EDT - 3 years ago

Pluri CEO Issues Shareholder Update

Jul 25, 2022, 1:00 AM EDT - 3 years ago

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

Jul 13, 2022, 9:59 AM EDT - 3 years ago

Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

Jul 13, 2022, 6:00 AM EDT - 3 years ago

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Mar 28, 2022, 3:00 AM EDT - 3 years ago

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

Mar 23, 2022, 7:30 AM EDT - 3 years ago

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

Mar 8, 2022, 7:12 AM EST - 3 years ago

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

Mar 2, 2022, 7:00 AM EST - 3 years ago

Pluristem CEO Issues Shareholder Update

Feb 24, 2022, 7:00 AM EST - 3 years ago

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

Jan 10, 2022, 6:26 AM EST - 3 years ago

Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform

Jan 10, 2022, 3:00 AM EST - 3 years ago

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Dec 27, 2021, 7:00 AM EST - 3 years ago

Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Nov 15, 2021, 7:10 AM EST - 3 years ago

Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Nov 10, 2021, 7:00 AM EST - 3 years ago

Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform